GOG-0219
|
GOG
|
A Phase III; Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2; IIA; IIB; IIIB; and IVA Cervical Carcinoma Limited to the Pelvis
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0240
|
GOG
|
A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865; IND #113912) Versus the Non-Platinum Doublet; Topotecan Plus Paclitaxel; with and without NCI-Supplied Bevacizumab; in Stage IVB; Recurrent or Persistent Carcinoma of the Cervix
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0241
|
GOG
|
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0249
|
GOG
|
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk; Early Stage Endometrial Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0250
|
GOG
|
A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0252
|
GOG
|
A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0258
|
GOG
|
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked; Advanced Endometrial Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
GOG-0261
|
GOG
|
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV; Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus; Fallopian Tube; Peritoneum or Ovary
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0262
|
GOG
|
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
GOG-0263
|
GOG
|
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk; Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|